TrxR3 Inhibitors

Chemical inhibitors of TrxR3 encompass a variety of compounds that interact with the protein to impede its function. Aurothioglucose and Gold Sodium Thiomalate, for instance, target the selenocysteine residue that is pivotal for the catalytic activity of TrxR3. They bind to this residue and obstruct the redox function that is central to the protein's activity. Similarly, Ethaselen directs its action towards the selenocysteine residue, leading to a disruption of the thioredoxin system by inhibiting TrxR3. Motexafin gadolinium operates by mimicking the substrate of TrxR3, binding irreversibly to the protein's active site and thereby competitively inhibiting its function. Cadmium chloride and Arsenic trioxide interact with TrxR3 by binding to its cysteine residues, which induces conformational changes that are detrimental to the enzyme's activity. These alterations in the structure of TrxR3 prevent it from carrying out its normal enzymatic reactions.

Cisplatin and Curcumin exert their inhibitory effects by modifying the active site of TrxR3. Cisplatin achieves this by binding to the selenol-thiol groups, whereas Curcumin forms a covalent bond with active site residues, both leading to a decline in TrxR3 activity. Auranofin, on the other hand, forms irreversible bonds with the active site thiol groups of TrxR3, which inhibits the reduction of thioredoxin, an essential process for maintaining cellular redox balance. Selenodiglutathione and Selenite are particularly unique in their interaction with TrxR3; they induce the formation of TrxR3-selenide complexes that render the enzyme inactive. Lastly, Nitrofurantoin interacts with the disulfide bridge in TrxR3's active center, reducing it to a stable and inactive complex, thereby inhibiting the enzyme's activity. Each of these chemicals utilizes a specific mechanism to inhibit the function of TrxR3, effectively blocking the biochemical pathways in which TrxR3 is involved.